Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 0.1% during mid-day trading on Monday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...